Health & Healthcare

TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”), has begun providing its remote health monitoring system “REMONY,” powered by the recharge-free smart tracker MOTHER Bracelet^®, to the Japan Ground Self-Defense Force (JGSDF).

■Background of the Deployment

In recent years, the importance of health management and heatstroke prevention for personnel operating under extreme conditions has grown significantly. Traditional wearable devices often face limitations in such environments—particularly in mountainous or remote areas where power supply is scarce—making it challenging to collect vital health data or detect anomalies in real-time continuously.

To address these challenges, there has been increasing demand in the field for devices that are lightweight, highly energy-efficient, and capable of long-term use without requiring recharging. In response, the Japan Ground Self-Defense Force 8th Division has adopted “REMONY,” a remote health monitoring system powered by the MOTHER Bracelet^®, a recharge-free smart tracker developed by MOTHER Labs.

The MOTHER Bracelet^® utilizes thermoelectric generation technology, enabling uninterrupted operation throughout training periods without concerns about battery depletion. This capability was a key factor in its adoption. By leveraging this technology, commanding officers and medical staff can remotely monitor the real-time health conditions of individual personnel during extended missions, allowing them to proactively identify risks such as heatstroke and take preventive measures before health-related issues escalate.

■About the Japan Ground Self-Defense Force 8th Division

The Japan Ground Self-Defense Force 8th Division is responsible for the defense of southern Kyushu and disaster relief operations in the region. The division conducts a wide range of training and missions to ensure the safety and security of local communities.
HP: https://www.mod.go.jp/gsdf/wae/8d

■About the MOTHER Bracelet, Recharge-Free Smart Tracker

MOTHER Bracelet is the world’s first* 24/7 recharge-free smart tracker. It uses innovative technology from a Silicon Valley tech company that allows for power generation based on temperature differences between body and surrounding air. The recharge-free feature eliminates the risk of data loss when a device is taken off for recharge. MOTHER Bracelet records five basic metrics: heart rate, calories burned, body surface temperature, step count, and sleep.
Official Website: https://mother-bracelet.com

◾️About REMONY, Remote Health Monitoring System

REMONY, a remote health monitoring system, developed by MOTHER Labs, combines the wrist-worn recharge-free smart tracker MOTHER Bracelet with a dedicated gateway. The system enables automatic data synchronization and centralized real-time management. Health monitoring with conventional wearables often faces challenges due to data loss during device recharge period. However, MOTHER Bracelet measures user vital data in real-time 24/7 without needing removal for recharge. As a result, it allows prompt and early detection of health emergencies and accident prevention with high accuracy. The system is customizable for use in various industries, including elderly care, health monitoring for night shift workers, etc.

【Features】

• Measurement and display of heart rate, skin temperature, step count, sleep duration, and calories burned
• Various alert functions (fall detection, abnormal heart rate, heatstroke, SOS call, etc.)
• Automatic notification functions linked to alerts

■ABOUT MEDIROM MOTHER Labs Inc.

A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the health- tech sector. The company’s core activities include the ‘Specific Health Guidance Program’ offered through the ‘Lav’ health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.

MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web: https://medirom.co.jp/en

◼︎MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web: https://medirom.co.jp/en
Contact: ir@medirom.co.jp

■Forward-Looking Statements Regarding MEDIROM

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:

● MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;

● changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets;

● MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment;

● the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies;

● MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;

● MEDIROM’s ability to raise additional capital on acceptable terms or at all;

● MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments;

● changes in consumer preferences and MEDIROM’s competitive environment;

● MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and

● the regulatory environment in which MEDIROM operates.

More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/e8aecd5d-c015-40be-afcc-342d98c2b00b

https://www.globenewswire.com/NewsRoom/AttachmentNg/30a30987-3d7b-4ff9-887d-e9a375138720

https://www.globenewswire.com/NewsRoom/AttachmentNg/691d7a8e-107e-42c2-a5be-c1ced53a097d

https://www.globenewswire.com/NewsRoom/AttachmentNg/ff1f55e1-811a-46a8-8946-01766924e357

https://www.globenewswire.com/NewsRoom/AttachmentNg/c65ac934-5699-489d-a5cf-904c18f41c1a

SAUDI ARABIA, Riyadh, Sept. 03, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) has reaffirmed its global standing as a pioneer in advanced medical technologies by successfully establishing in-house manufacturing and clinical application of CAR-T therapy, placing itself among the select global centers driving the future of precision medicine.

KFSHRC has administered the first dose of locally manufactured Lentigen CD19 CAR-T therapy to a patient enrolled in a Phase I clinical trial for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), marking a breakthrough moment for the Kingdom in advanced gene and cell therapies.

Since 2020, KFSHRC has treated more than 200 patients with CAR-T therapies manufactured abroad, before advancing to become the first institution in the Kingdom to both manufacture and administer an in-house CAR-T product under a Phase I clinical trial. Unlike conventional CAR-T, which requires overseas production, the hospital’s in-house platform has reduced costs to just 20% of commercial CAR-T, eliminated logistical delays, and accelerated access to potentially life-saving treatment.

This milestone reflects integrated collaboration between KFSHRC’s department of Hematology, stem of transplantation and  therapy, Research & Innovation (R&I), Department of Pathology & Laboratory Medicine (DPLM), Center for Genomic Medicine (CGM), and Clinical Research Department (CRD) combining research, manufacturing, and clinical care under one roof to reshape healthcare access and outcomes.

KFSHRC will showcase its pioneering role in cell and gene therapies as strategic partner of the C3 Davos of Healthcare™ New York Summit: Healthcare Disrupted – The Future of AI, Data & Precision Medicine. The event, hosted at the Union League Club in New York City, will provide a global platform for the hospital to highlight how locally developed CAR-T manufacturing capabilities are reshaping access, reducing costs, and advancing international standards of care.

By building local biomanufacturing capabilities, KFSHRC underscores its mission to advance Vision 2030 and the National Biotechnology Strategy, ensuring patients in Saudi Arabia and beyond benefit early from next-generation therapies while reinforcing its role as a global reference center for healthcare innovation.

It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centres for the second consecutive year and has been recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6c485d4-ac4c-4df3-9b9b-5a0cc7979618

RIYADH, Saudi Arabia, Aug. 30, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC), ranked 15th globally by Brand Finance, recorded a 47% surge in international patients in 2024, strengthening its position as a fast-growing destination for medical tourism under Saudi Arabia’s Vision 2030 to diversify the economy and expand high-value healthcare services.

The sharp rise significantly outpaces global benchmarks, where leading institutions typically record annual international patient growth in the low single digits. This momentum is underpinned by KFSHRC’s more than 50 years of expertise in tertiary and highly specialized healthcare, making it a trusted center for patients seeking advanced and complex treatment.

KFSHRC’s international appeal is anchored in its record of world-first achievements in complex specialties, including robotic liver and heart transplants, as well as leadership in advanced gene and cell therapies. These milestones underscore both the hospital’s role as a global center of excellence and Saudi Arabia’s ambition to emerge as a hub for advanced medical care.

KFSHRC’s momentum is further supported by Saudi Arabia’s geographic location, which places the Kingdom within a six-to-eight-hour flight from Europe, Africa, and much of Asia. In the post-COVID era, this accessibility has become a decisive factor, as patients increasingly seek shorter travel distances for complex medical treatments. This advantage enhances KFSHRC’s ability to sustain its rapid growth in international patient admissions and strengthens its position as one of the fastest-growing destinations for advanced care.

The growth of international admissions at KFSHRC reflects not only rising global confidence in Saudi medical expertise but also contributes directly to the Kingdom’s economic diversification goals, supporting the development of a sustainable and high-value healthcare sector under Vision 2030.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally among the world’s top 250 Academic Medical Centers for the second consecutive year. It has also been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. In addition, Newsweek magazine included KFSHRC in the World’s Best 250 Hospitals and the World’s Best Smart Hospitals 2025 lists.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/945b1b8f-80b9-4a76-af87-9893590b1a19

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) — Chronic wounds remain one of the toughest challenges in modern healthcare. Dimora Medical, a company dedicated to simplifying chronic disease care for aging populations, today launches Dimora PHMB Skin and Wound Cleanser to help close that gap in chronic wound care. Research shows that more than 78% of chronic wounds are complicated by biofilms, which are protective layers of bacteria that slow healing and increase infection risk. The PHMB Skin and Wound Cleanser is designed to break down stubborn biofilms and kill 99.99% of bacteria within minutes. Simple to use and backed by strong clinical evidence, it helps caregivers protect loved ones more effectively while easing the burden of home wound care.

Breaking Down Biofilms for Faster Healing

One of the standout features of the Dimora PHMB Skin and Wound Cleanser is its ability to tackle biofilms, a hidden barrier that makes chronic wounds so hard to treat. Biofilms are slimy layers formed by bacteria on the wound surface. They protect microbes from the body’s defenses and from treatments, often delaying healing and raising the risk of infection.

The cleanser’s main ingredient, Polyhexamethylene Biguanide (PHMB), has been shown to break down these biofilms quickly and effectively. In tests, PHMB removed 99.49% of biofilm within three minutes and reached 99.99% after seven minutes. Once the biofilm barrier is cleared, antimicrobial dressings and the body’s natural healing process can work as intended. Compared with hypochlorous or saline-based solutions, PHMB has consistently demonstrated stronger activity against biofilms of common wound pathogens like Staphylococcus aureus and Pseudomonas aeruginosa.

For caregivers at home, this means fewer complications, less risk of infection, and a more reliable path to wound healing. It’s an advanced solution that brings clinical-level effectiveness into everyday care.

Rapid Antimicrobial Power for Safer Home Care

Beyond clearing biofilms, the Dimora PHMB Skin and Wound Cleanser works as an antiseptic skin cleanser, delivering fast and powerful antimicrobial action. For infected wounds, it kills 99.99% of bacteria in just two minutes. For non-infected wounds, that same level of protection is reached in as little as one minute. That kind of speed matters in home care, where infection risk is high and every delay can slow recovery.

In practical terms, this means a caregiver can clean and protect a wound quickly without multiple steps or long waiting times. Families managing diabetic foot ulcers, post-surgical incisions, or even everyday cuts in older adults know that speed makes a difference. Each application reduces the chance of infection, lowers stress for the caregiver, and keeps the patient more comfortable at home. By minimizing complications, the cleanser also helps families avoid repeat clinic visits and gives them greater confidence in daily wound management.

Long-Lasting Protection Families Can Count On

Consistency matters in wound care, especially for families managing chronic conditions day after day. The Dimora PHMB Skin and Wound Cleanser isn’t just effective the first time you use it—it maintains its antimicrobial strength over time. In testing under USP <51>, an internationally recognized standard for antimicrobial effectiveness, the cleanser exceeded expectations. Even after being opened for 28 days, it still delivered a 99.99% reduction in bacteria, ensuring safety and stability with every use. For caregivers at home, this reliability goes beyond a technical detail. It means fewer worries about whether a bottle has lost its strength or needs to be replaced too quickly. By contrast, hypochlorous-based solutions are less stable and less effective against wound pathogens over time. PHMB gives families peace of mind and consistent performance. With Dimora, caregivers can spend less energy tracking expiration dates and more time focusing on what truly matters—supporting their loved one’s healing.

Making Home Care Easy, Reliable, and Safe

Dimora’s vision is clear: make home care easy and become the trusted wound care expert for families. The PHMB Skin and Wound Cleanser reflects that mission by bringing clinical strength into everyday use. Acting as a wound wash, antiseptic skin cleanser, and reliable antibacterial wash, it supports chronic wound care at home. From diabetic foot ulcers to surgical sites, its proven biofilm removal gives patients a better path to healing and provides caregivers with real peace of mind.

For families, that means fewer complications, less stress, and safer home care with every use. The Dimora PHMB Skin and Wound Cleanser is available now for $15.99 on Amazon

About Dimora

Dimora develops advanced solutions for chronic disease and wound care. With 34 years of experience in medical supplies, Dimora is dedicated to making home care easy, safe, and less stressful for families.

Press Contact：
Contact Person: Alisa Yen
Email：support@dimoramedical.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/691ce3e6-9d2f-4b49-88a1-078a31cc6512

https://www.globenewswire.com/NewsRoom/AttachmentNg/05cd46b1-df6b-4f45-8469-b8546751325e

https://www.globenewswire.com/NewsRoom/AttachmentNg/c2316217-dc99-40f6-8b1e-0788ee2a520e

https://www.globenewswire.com/NewsRoom/AttachmentNg/06def58c-5435-41cb-a130-2c007cae88c8